A kind of enantiobestane type diterpene lactone compound and its preparation method and application
By extracting and preparing enantiorosin alkyl diterpenoid lactone compounds from Wolf Venom, the problem of extraction of anti-cancer substances in herbs was solved, effective inhibition of a variety of cancer cells was achieved, and new anti-antibody was provided The development direction of cancer drugs.
Patent Information
- Application Number
- CN202310901531.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-07-21
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2043-07-21
AI Technical Summary
The prior art is difficult to extract natural products with inhibiting cancer cells from herbs, especially enantiorosin alkyl diterpene lactone compounds, and there is no patent or documentary report, and effective anti-cancer drugs are lacking.
By diafiltration, extraction, column chromatography gradient elution and other steps, an enantiorosin alkyl diterpene lactone compound with inhibitory effect was prepared and applied to anticancer drugs. development.
It has achieved effective inhibition of six cancer cells (MCF-7, HCC1806, Hela, A549, PC-3 and H460), providing new anti-cancer drugs with ideas and ways to develop, and has good inhibitory effect and development value.
Smart Images

Figure CN117106008B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of natural medicines, and in particular to an enantiobistane-type diterpene lactone compound, a preparation method and application thereof. Background Art
[0002] Cancer is one of the most serious diseases threatening human health. Its mortality rate is second only to cardiovascular and cerebrovascular diseases, and its incidence rate is increasing year by year. Although chemotherapy, the mainstay of tumor treatment, has good efficacy, it often causes severe side effects, making it difficult for patients to adhere to treatment. In addition, most cancers lack effective targeted therapies, are insensitive to endocrine therapy and conventional chemotherapy, are highly invasive, and have a poor prognosis, making their clinical treatment a very difficult problem. Therefore, it is necessary to seek treatments and drugs with good efficacy and minimal toxic side effects. In recent years, Traditional Chinese Medicine has provided an important source and new opportunities for modern drug development. The active ingredients of natural products, with their multi-target, high efficiency, and low toxicity, have become an important source of new drug research and development.
[0003] Euphorbia chamaejasme, a perennial herbaceous plant of the Euphorbiaceae family, has a fleshy, cylindrical root with white latex. It is one of the original plants of the traditional Chinese medicine wolfsbane. It is pungent, flat, and toxic, and enters the liver and spleen meridians. It has the effect of dispersing nodules and killing insects, and is widely used in Chinese patent medicines and clinical prescriptions. In traditional medicine, wolfsbane is used to treat phlegm, food, and insect accumulation, edema and abdominal distension, abdominal pain, accumulation of tumors, lymph tuberculosis, scabies, etc. Modern research results show that the traditional Chinese medicine wolfsbane has multiple pharmacological activities, such as anti-tuberculosis, anti-HIV virus, anti-tumor, antibacterial, anti-inflammatory, and insecticidal effects. Modern research shows that the chemical components of wolfsbane euphorbia mainly include two major categories: phenolic acids and terpenes. Among them, terpenes are mainly rich and diverse diterpenes, which are also considered to be the main material basis for the numerous pharmacological activities of wolfsbane euphorbia. Enantioabietan-type diterpenes are important chemical components of Euphorbia chamaejasma. To date, there have been no patents or literature reports on the novel enantioabietan-type diterpenoid lactone compounds and their activities involved in the present invention.
[0004] Therefore, whether natural products with the ability to inhibit cancer cells can be extracted from herbal plants has become a technical problem that needs to be urgently solved by those skilled in the art. Summary of the Invention
[0005] The present invention provides an enantiobistane-type diterpene lactone compound and its preparation method. The compound has a good inhibitory effect on six cancer cell types: MCF-7, HCC1806, Hela, A549, PC-3, and H460. The specific technical solution is as follows:
[0006] An enantiobetic diterpene lactone compound, wherein the enantiobetic diterpene lactone compound has a structure shown in the following formula I:
[0007]
[0008] A method for preparing the enantioabietan-type diterpene lactone compound represented by formula I, characterized by comprising the following steps: using the dried root of Euphorbia chamaejasme as raw material, extracting and concentrating the dried root through diafiltration to obtain an extract, suspending the extract in water to obtain a suspension, and extracting and concentrating the extract to obtain an extract;
[0009] The extract is subjected to gradient elution by neutral alumina column chromatography, silica gel column chromatography, and MCI resin column chromatography, and then eluted by ODS medium-pressure column chromatography to obtain Fr.1-Fr.6. Fr.6 is purified by ODS liquid chromatography to obtain the enantioabietane-type diterpene lactone compound shown in formula I.
[0010] Furthermore, gradient elution is performed on the neutral alumina column chromatography to obtain a first eluate, the eluent is petroleum ether-ethyl acetate-methanol, and the volume ratio of petroleum ether, ethyl acetate and methanol is 100:0:0 to 0:0:100. Specifically, the eluent includes eluents with a volume ratio of petroleum ether-ethyl acetate-methanol of 100:0:0, 90:10:0, 80:20:0, 50:50:0, 30:70:0, 27:75:0, 0:100:0, 0:50:50, and 0:0:100, and 9 eluates are collected segmentally after gradient elution with the eluent.
[0011] Furthermore, the first eluate is subjected to gradient elution on the silica gel column chromatography to obtain a second eluate, the eluent being petroleum ether-acetone-methanol, and the volume ratio of the petroleum ether, acetone, and methanol being 100:0:0 to 0:100:0 to 0:0:100. Specifically, the eluent includes eluents having a volume ratio of petroleum ether-acetone-methanol of 100:0:0, 95:4.5:0.5, 90:9.5:0.5, 85:14:1, 80:19:1, 48:48:2, 20:75:5, and 0:0:100, and 8 eluates are collected segmentally after gradient elution with the eluent.
[0012] Further preferably, the first eluate is obtained by eluting with an eluent having a volume ratio of petroleum ether, ethyl acetate and methanol of 30:70:0.
[0013] Furthermore, the second eluate is subjected to gradient elution on the MCI resin column chromatography to obtain a third eluate, wherein the eluent is methanol-water, and the volume ratio of the methanol to water is 30:70 to 80:20. Specifically, the eluent includes eluents having a methanol-water volume ratio of 0:100, 30:70, 50:40, 70:30, 90:10, and 100:0, and six eluates are collected in stages after gradient elution with the eluent.
[0014] Further preferably, the second eluate is obtained by eluting with an eluent having a volume ratio of petroleum ether, acetone and methanol of 85:14:1.
[0015] Furthermore, the third eluate was subjected to isocratic elution on the ODS medium-pressure column chromatography to obtain Fr.1 to Fr.6, and the mobile phase was methanol-water, with the volume ratio of methanol to water being 60:40.
[0016] Further preferably, the third eluate is obtained by eluting with an eluent having a volume ratio of methanol to water of 70:30.
[0017] Further preferably, the flow rate of eluting the third eluate through the ODS medium-pressure column chromatography is 20 mL / min, and the elution time is 4 hours.
[0018] Furthermore, Fr.6 was eluted by ODS liquid chromatography with a fixed ratio mobile phase to obtain a low-purity compound represented by formula I, wherein the mobile phase was acetonitrile-water, and the volume ratio of acetonitrile to water was 40:60.
[0019] Furthermore, the low-purity compound represented by formula I is purified by ODS liquid chromatography using methanol-water solution as the mobile phase to obtain the compound represented by formula I, wherein the volume ratio of methanol to water is 65:35.
[0020] Furthermore, the filtration extraction step is as follows: taking ethanol to filtration extract the dried root of the wolfsbane Euphorbia at room temperature, and obtaining an extract-like ethanol extract after concentration, and suspending the ethanol extract in water to obtain a suspension; the ethanol concentration is 95%, the filtration extraction time is 120h, and the ethanol filtration extraction flow rate is 0.5L / h.
[0021] Furthermore, the extraction step is as follows: adding dichloromethane in an equal volume to the suspension, extracting and concentrating to obtain the extract.
[0022] A use of the enantioabietane-type diterpene lactone compound represented by formula I in the preparation of anticancer drugs.
[0023] Furthermore, the enantiabietane-type diterpene lactone compound is used as a raw material to prepare an anticancer pharmaceutical composition or any pharmaceutically acceptable salt thereof.
[0024] Furthermore, the pharmaceutical composition or any pharmaceutically acceptable salt is in the form of tablets, capsules, granules, oral liquids, granules, pills or pellets.
[0025] More preferably, the cancer is breast cancer, cervical cancer, lung cancer, prostate cancer and lung cancer.
[0026] One or more technical solutions provided in the embodiments of the present invention have at least the following technical effects or advantages:
[0027] This study, published in Nature Communications, for the first time, has extracted enantioabietan-type diterpenoid lactone compounds from Euphorbia chamaejasma that exhibit anticancer properties. These compounds exhibit potent inhibitory effects against six cancer cell lines: MCF-7, HCC1806, Hela, A549, PC-3, and H460. These compounds hold great promise as novel anticancer drugs, and their design offers new insights and avenues for their development. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The enantiobistane-type diterpene lactone compound of the present invention 1 H-NMR spectrum;
[0029] Figure 2 The enantiobistane-type diterpene lactone compound of the present invention 13 C-NMR spectrum;
[0030] Figure 3 is a curve diagram showing the inhibition rate of the enantiobistane-type diterpene lactone compounds of the present invention on MCF-7 cells;
[0031] Figure 4 is a curve diagram showing the inhibition rate of the enantiobistane-type diterpene lactone compounds of the present invention on HCC1806 cells;
[0032] Figure 5 is a curve diagram showing the inhibition rate of the enantiobistane-type diterpene lactone compounds of the present invention on Hela cells;
[0033] Figure 6 is a curve diagram showing the inhibition rate of the enantiobistane-type diterpene lactone compounds on A549 cells;
[0034] Figure 7 is a curve diagram showing the inhibition rate of the enantiobistane-type diterpene lactone compounds of the present invention on PC-3 cells;
[0035] Figure 8 The graph is a graph showing the inhibition rate of the enantioabietane-type diterpene lactone compounds on H460 cells. DETAILED DESCRIPTION
[0036] In order to better understand the above technical solution, the above technical solution will be described in detail below with reference to the accompanying drawings and specific implementation methods.
[0037] An enantioabietan-type diterpene lactone compound having the structure shown in the following formula I:
[0038]
[0039] The method for preparing the enantioabietane-type diterpene lactone compound includes the following embodiments:
[0040] Example 1
[0041] 1 kg of dried medicinal materials of wild wolf chamaejasma root from high altitude was used as raw material, and 95% ethanol was used for percolation extraction for 120 hours at a flow rate of 0.5 L / h. The extract was concentrated by rotary evaporation to obtain an ethanol extract in the form of an extract. The ethanol extract was suspended in water to obtain a suspension, and dichloromethane with a volume equal to that of the suspension was added for extraction. The extract solution was concentrated to obtain an extract. The dichloromethane extract was subjected to neutral alumina column chromatography and gradient eluted with a petroleum ether-ethyl acetate-methanol solution with a volume ratio of 100:0:0 to 0:0:100. Specifically, the eluent included eluents with a volume ratio of petroleum ether-ethyl acetate-methanol of 100:0:0, 90:10:0, 80:20:0, 50:50:0, 30:70:0, 27:75:0, 0:100:0, 0:50:50, and 0:0:100. After gradient elution with the eluent, 9 eluates were collected segmentally. The eluate eluted with an eluent having a volume ratio of petroleum ether-ethyl acetate-methanol of 30:70:0 was subjected to silica gel column chromatography and gradient elution was performed with a petroleum ether-acetone-methanol solution having a volume ratio of 100:0:0 to 0:100:0 to 0:0:100. Specifically, the eluent includes eluents having a volume ratio of petroleum ether-acetone-methanol of 100:0:0, 95:4.5:0.5, 90:9.5:0.5, 85:14:1, 80:19:1, 48:48:2, 20:75:5, and 0:0:100. After gradient elution with the eluent, 8 eluates were collected segmentally. The eluate eluted with the eluent having a volume ratio of petroleum ether, acetone, and methanol of 85:14:1 was subjected to MCI resin column chromatography and gradient eluted with a methanol-water solvent having a volume ratio of 0:100 to 100:0. Specifically, the eluent included eluents having a volume ratio of methanol to water of 0:100, 30:70, 50:40, 70:30, 90:10, and 100:0. Six eluates were collected in stages after the gradient elution. The eluate eluted with the eluent having a volume ratio of 70:30 methanol to water was subjected to ODS medium-pressure column chromatography and isocratically eluted with a methanol-water solvent having a volume ratio of 60:40 at a flow rate of 20 mL / min for 4 hours. After elution, six components Fr.1 to Fr.6 were obtained. Fraction Fr.6 was purified by Waters fully automated preparative ODS liquid chromatography using an acetonitrile-water solution in a volume ratio of 40:60 as the mobile phase to obtain a low-purity compound of Formula I. The low-purity compound of Formula I was purified by ODS liquid chromatography using a methanol-water solution in a volume ratio of 65:35 as the mobile phase to obtain the compound of Formula I.
[0042] The present invention also provides an embodiment of the use of an enantiobistane-type diterpene lactone compound represented by Formula I in the preparation of anticancer drugs.
[0043] Specifically, the enantiobistane-type diterpene lactone compound is used as a raw material to prepare an anticancer pharmaceutical composition or any pharmaceutically acceptable salt thereof. The pharmaceutical composition is added with an excipient, which is not particularly limited in the present invention and can be any suitable excipient known to those skilled in the art.
[0044] The dosage form of the pharmaceutical composition or any pharmaceutically acceptable salt is tablets, capsules, granules, oral liquids, granules, pills or pellets.
[0045] Example 2:
[0046] The structure of the compound represented by formula I prepared in Example 1 was identified.
[0047] The identification results are as follows:
[0048] The compound represented by formula I is a white amorphous powder (methanol) and is easily soluble in methanol and dichloromethane. 10% sulfuric acid ethanol solution shows purple-red color. Figure 1 As shown in Table 1, 1 The H-NMR (600 MHz, DMSO-d6) spectrum showed four methyl hydrogen proton signals δ H 2.10 (3H, d, J = 1.8 Hz, Me-17), 0.81 (3H, s, Me-18), 0.82 (3H, s, Me-19), 0.57 (3H, s, Me-20), two oxidized methine proton signals δ H 5.70 (1H, m), 3.93 (1H, d, J = 3.6 Hz). Figure 2 As shown in Table 1, 13 The C-NMR (150 MHz, DMSO-d6) spectrum showed 20 carbon signals: C 147.5 (C-13) and 134.6 (C-15) suggest that there is a pair of double bonds in the structure, δ C 72.6 (C-8), 74.0 (C-11), and 86.3 (C-14) are three carbon signals connected to oxygen. C 173.2 (C-16) is the ester carbonyl carbon signal, δ C193.6 (C-12) is a ketone carbonyl carbon signal. Combining the above physicochemical properties and spectral data analysis, it was found through literature search that the data of the compound of formula I is basically consistent with the data of 11-oxo-ebracteolatanolideB in the literature. The difference is that the HMBC correlation between the oxymethyl proton signal and the carbon signal in the structure is inconsistent. The HMBC spectrum of the compound of formula I shows that there is a correlation between H-11 and C-8, C-9, C-10, C-12 and C-13. Combined with the H-HCONSY spectrum, it is observed that H-9 and H-11 are correlated, so it is speculated that there are hydroxyl substitutions at the C-8 and C-11 positions, and the C-12 position is a ketone carbonyl. The HMBC spectrum shows that there is a correlation between H-14 and C-7, C-9, C-13, and C-15, so it is speculated that the five-membered lactone ring occurs between C-14 and C-16, and the planar structure of the compound is determined. The relative configuration was determined by NOESY, and H-5 (δ H 1.60) and H-9(δ H 1.87), H-9 and HO-11 (δ H 6.53), HO-8(δ H 5.40) and HO-11, H-9 and H-14 (δ H 5.70), H-14 and HO-11 were NOE-correlated, indicating that H-5, H-9, HO-8, HO-11, and H-14 were located on the same side.
[0049] Through the above analysis, it was finally determined that the compound of formula I is a new enantioabietan-type diterpene lactone compound of the present invention, in which a five-membered lactone D ring is formed between C-14 and C-16.
[0050] Table 1 Compounds of formula I 1 H-NMR (600 MHz, DMSO-d6) and 13 C-NMR (150 MHz, DMSO-d6) data
[0051]
[0052]
[0053] Example 3: Pharmacological activity of compounds of formula I
[0054] Test methods and results
[0055] 1. MTT assay to detect the effect of compound I on the proliferation of six cancer cells: MCF-7, HCC1806, Hela, A549, PC-3 and H460
[0056] Six cancer cells in the logarithmic growth phase were selected and digested with trypsin. The cells were then cultured in the corresponding culture medium containing 10% fetal bovine serum to a cell concentration of 5 × 10 4 / mL cell suspension, plated (100 μL, 5×10 3 Each well of the experimental group was replaced with 100 μL of test compound culture medium at different concentrations, and the DMSO content in the system was controlled within 0.5%. Each concentration was repeated in triplicate. The control group was replaced with blank culture medium containing the same proportion of DMSO, and the wells without cells were used as background. The cells were incubated under the above conditions for 48 hours. After completion, the cells were washed twice with PBS, and 20 μL of freshly prepared 0.5 mg / mL MTT culture medium was added. The cells were incubated under the above conditions for 4 hours. The upper culture medium was discarded, 100 μL of DMSO was added, and the cells were shaken for 10 minutes to completely dissolve the crystals. The 96-well plate was placed in a microplate reader and the OD value at 492 nm was measured. The tumor cell growth inhibition rate of the test compound was calculated as follows: Cell growth inhibition rate % = (A(negative control group) - A(drug administration group)) / A(negative control group) × 100%
[0057] The experimental data were analyzed using SPSS 17.0 statistical software, and the cell proliferation inhibitory activity of the samples was evaluated using the half-maximal inhibitory concentration.
[0058]
[0059] A G is the average OD value of the drug-treated group, A K is the average OD value of the blank control group, A M is the average OD value of the model group.
[0060] 2. Anticancer activity results of compounds of formula I and formula II
[0061] By preliminary screening of the effects of the compound of formula I on the proliferation of six cancer cells, MCF-7, HCC1806, Hela, A549, PC-3 and H460, it was found that the two compounds of formula I had significant inhibitory activity against all six cancer cells.
[0062] When the concentration of the compound of formula I is 100 μM, the inhibition rates on six cancer cells MCF-7, HCC1806, Hela, A549, PC-3 and H460 are 99%, 100%, 100%, 100%, 100% and 100%, respectively; Figure 3-Figure 8 The data show that the IC values of the compound of formula I against 6 types of cancer cells are 50The values were 11.38±0.62, 0.12±0.01, 5.39±0.24, 2.45±0.09, 0.31±0.01 and 3.94±0.71 μM, respectively.
[0063] In summary, this invention represents the first discovery of anticancer enantiobetic diterpene lactone compounds from Euphorbia chamaejasma. These compounds exhibit potent inhibitory effects against six cancer cell lines: MCF-7, HCC1806, Hela, A549, PC-3, and H460. These compounds hold great promise as novel anticancer drugs, and their design strategy provides new insights and approaches for their development.
[0064] Although the preferred embodiments of the present invention have been described, those skilled in the art may make additional changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0065] Obviously, those skilled in the art may make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if such changes and modifications fall within the scope of the claims and their equivalents, the present invention is intended to include such changes and modifications.
Claims
1. An enantioabietanene-type diterpene lactone compound, Features: The enantioabietane-type diterpene lactone compound has a structure shown in the following formula (I):
2. A method for preparing the enantioabietane-type diterpene lactone compound according to claim 1, Features: The following steps are involved: The dried root of Euphorbia chamaejasme is used as a raw material, ethanol is used for percolation extraction of the dried root of Euphorbia chamaejasme at room temperature, and an ethanol extract in the form of an extract is obtained after concentration, and the ethanol extract is suspended in water to obtain a suspension; the ethanol concentration is 95%, the percolation extraction time is 120 hours, and the percolation extraction flow rate of the ethanol is 0.5 L / h; dichloromethane is added in an amount equal to the volume of the suspension, and the suspension is concentrated after extraction to obtain an extract; The extract is subjected to gradient elution through neutral alumina column chromatography, the eluent is petroleum ether-ethyl acetate-methanol, and the volume ratio of petroleum ether, ethyl acetate and methanol is 100:0:0 to 0:0:100; The eluate eluted with the eluent having a volume ratio of petroleum ether-ethyl acetate-methanol of 30:70:0 is subjected to gradient elution by silica gel column chromatography, wherein the eluent is petroleum ether-acetone-methanol, and the volume ratio of petroleum ether, acetone and methanol is 100:0:0-0:100:0-0:0:100; The eluate eluted with the eluent of petroleum ether-acetone-methanol in a volume ratio of 85:14:1 is subjected to gradient elution by MCI resin column chromatography, the eluent is methanol-water, and the volume ratio of methanol to water is 30:70-80:20; The eluate eluted with the eluent having a volume ratio of methanol to water of 70:30 was subjected to ODS medium pressure column chromatography to obtain Fr.1 to Fr.6, the mobile phase was methanol-water, and the volume ratio of methanol to water was 60:40; Fr.6 was subjected to ODS liquid chromatography and eluted with a fixed ratio mobile phase to obtain a low-purity compound represented by formula I, wherein the mobile phase was acetonitrile-water, and the volume ratio of acetonitrile to water was 40:60; The low-purity compound represented by formula I is purified by ODS liquid chromatography using methanol-water as the mobile phase to obtain the compound represented by formula I, wherein the volume ratio of methanol to water is 65:
35.
3. Use of the enantioabietane diterpene lactone compound according to claim 1 in the preparation of drugs for treating breast cancer, cervical cancer, prostate cancer and lung cancer.
4. The use according to claim 3, It is characterized in that The enantiabietane-type diterpene lactone compound is used as a raw material to prepare a pharmaceutical composition for preventing breast cancer, cervical cancer, prostate cancer or lung cancer or any pharmaceutically acceptable salt thereof.
Citation Information
Patent Citations
Abietane-type diterpene compound in euphorbia fischeriana steud and preparing method
CN106279081A
Abietane type diterpenoid compound with anti-tumor effect, preparation method, pharmaceutical composition and application
CN113307785A
Novel diterpene compound as well as preparation method, pharmaceutical composition and application thereof in antitumor drugs
CN115626932A
